Search clinical trials for: Docetaxel

Total 2406 results

Introgen Therapeutics

Completed

Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer

Locally Advanced Breast Cancer (LABC)

United States
University of Michigan Rogel Cancer Center

Terminated

Companion Pharmacogenetic Study to UMCC 9900/9901

Metastatic Breast Cancer

United States
Sanofi

Terminated

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Hong Kong
AZ-VUB
Sanofi

Unknown

Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

Belgium
Gachon University Gil Medical Center

Completed

Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC

Advanced Non-Small Cell Lung Cancer

Korea, Republic of
Gachon University Gil Medical Center

Unknown

Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC

Non-Small Cell Lung Cancer

Korea, Republic of
Millennium Pharmaceuticals, Inc.

Completed

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Millennium Pharmaceuticals, Inc.

Completed

Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer

Prostatic Neoplasms

United States
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Breast Cancer

Greece
MedImmune LLC

Completed

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

Prostate Cancer

United States, Belgium, Israel, Russian Federation, Canada, Hungary, Poland
National Cancer Center, Korea

Unknown

Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer

Stomach Neoplasms

Korea, Republic of
Emory University
Novartis

Terminated

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma

Gastric Adenocarcinoma

United States
Maxygen Holdings Ltd.
Parexel; Maxygen ApS; Maxygen, Inc.

Unknown

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy

Breast Cancer | Chemotherapy-Induced Neutropenia

Poland, Romania, Russian Federation, Ukraine
Cytogen Corporation

Unknown

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

Prostatic Neoplasms

United States
AstraZeneca

Completed

Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer

Metastatic Breast Cancer

Norway
NSABP Foundation Inc
AstraZeneca

Completed

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Breast Neoplasms

United States
AstraZeneca

Completed

Iressa 2nd Line Phase III Study in Japan

Non-Small Cell Lung Cancer

Japan
University of Washington
Aventis Pharmaceuticals

Completed

Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer

Breast Neoplasm

United States
University of Washington
Sanofi

Completed

Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer

Prostate Cancer

United States
Geriatric Oncology Consortium
Sanofi

Completed

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

Prostate Cancer

United States
Geriatric Oncology Consortium
Sanofi

Terminated

Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel

Breast Cancer | Lung Cancer

United States
Novacea

Terminated

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

Prostate Cancer

United States, Canada, Germany, Romania, Czech Republic, Former Serbia and Montenegro, Hungary, Puerto Rico, Slovakia
University Hospital, Bonn
Sanofi

Unknown

Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer-Prospective, Randomized Phase II Clinical Trial (PRIMOVAR-1)

Ovarian Neoplasms

Germany
German Breast Group

Completed

German Preoperative Adriamycin Docetaxel Study

Breast Neoplasms
Sanofi

Completed

TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN

Carcinoma, Squamous Cell

Korea, Republic of
Sanofi

Completed

TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian

Ovarian Neoplasms

Korea, Republic of
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Connective Tissue Oncology Society; Massachusetts... and other collaborators

Completed

Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

Sarcoma, Soft Tissue

United States
Herlev Hospital
Eli Lilly and Company; Sanofi

Completed

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

Prostate Cancer

Denmark
Fudan University

Unknown

Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer

Breast Neoplasms | Chemotherapy | Adjuvant

China
Gachon University Gil Medical Center
Sanofi

Unknown

Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC

Stomach Neoplasm | Recurrent | Stage IV

Korea, Republic of
National Taiwan University Hospital

Completed

Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer

Breast Cancer

Taiwan
Point Therapeutics

Completed

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Point Therapeutics

Terminated

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Carcinoma, Non-Small Cell Lung

United States
Eli Lilly and Company

Completed

Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents

Breast Neoplasms

France, Germany, Italy, Netherlands, Spain, United Kingdom
Finnish Breast Cancer Group
Sanofi; Hoffmann-La Roche; AstraZeneca

Completed

Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer

Breast Cancer

Finland
Pharmacyclics LLC.

Completed

Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

Breast Neoplasms | Lung Neoplasms | Prostatic Neoplasms | Ovarian Neoplasms

United States
Novacea
Aventis Pharmaceuticals

Completed

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
University of Saskatchewan
Sanofi

Terminated

Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers

Platinum Sensitive Relapsed Ovarian Cancer

Canada
Oncology Specialties, Alabama

Terminated

Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma

Metastatic Breast Cancer

United States
Charite University, Berlin, Germany

Completed

Docetaxel and Capecitabine in Advanced Gastric Cancer

Neoplasm Metastasis | Stomach Neoplasm

Germany
Cancer Research Network
Sanofi

Unknown

Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery

Breast Cancer

United States
Georgia Center for Oncology Research & Education
Sanofi

Unknown

Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer

Breast Neoplasms

United States
Eli Lilly and Company

Completed

A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer

Breast Neoplasms

United States
Memorial Sloan Kettering Cancer Center

Completed

Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Eli Lilly and Company
Aventis Pharmaceuticals

Completed

A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Italy
Gustave Roussy, Cancer Campus, Grand Paris

Suspended

Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients

Prostate Cancer

France
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer

Prostate Cancer

France
Novacea

Unknown

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Non Small Cell Lung Cancer (NSCLC) | Androgen Independent Prostate Cancer (AIPC)

Canada, United States
Zivena

Unknown

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

NSCLC

United States
Cell Genesys

Terminated

Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Prostate Cancer

United States

3

Subscribe